Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800338 | 0.77 | FFAR1 (0.36) | HTR1AADRA1ACHRM2CHRM5CHRM1 | |
| SCHEMBL6312002 | 0.68 | CHRM2 (0.34) | HTR1AADRA1ACHRM2CHRM5CHRM1 | |
| SCHEMBL8938553 | 0.65 | SLC6A2 (0.44) | — | |
| SCHEMBL487468 | 0.61 | IDO1 (0.48) | — | |
| SCHEMBL19101551 | 0.61 | TSHR (0.47) | HTR1AADRA1ACHRM2CHRM5CHRM1 | |
| SCHEMBL6197809 | 0.59 | CHRNB4 (0.39) | HTR1AADRA1ACHRM2CHRM5CHRM1 | |
| SCHEMBL1552525 | 0.59 | ADRA2C (0.47) | HTR1AADRA1A | |
| SCHEMBL1552526 | 0.59 | ADRA2C (0.47) | HTR1AADRA1A | |
| SCHEMBL6600049 | 0.58 | SLC7A5 (0.45) | — | |
| SCHEMBL801397 | 0.58 | ALDH1A1 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835735-B2 | Anticancer, tyrosine kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-12-28 | — | — | US | disclosed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | EGFR, ERBB2, ERBB4 | HTR1A 985/4885ADRA1A 920/4885CHRM2 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.